Astellas Pharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| YPHA.F | D4S.F | CUP.F | REC.MI | BIIB | ON4.F | |
|---|---|---|---|---|---|---|
| Market cap | 24.74B | 28.63B | 62.53B | 11.19B | 37.04B | 6.40B |
| P/E (TTM) | 12.2 | 21.6 | 23.9 | 22.6 | 45.1 | 15.1 |
| Forward P/E | — | 42.5 | 0.3 | 14.2 | 15.2 | — |
| Price/book | 2.3 | 3.0 | 5.5 | 5.2 | 2.0 | 1.3 |
| Dividend yield | 3.13% | 3.57% | 2.04% | 2.68% | — | 3.34% |
| 1-year change | +53.67% | −29.41% | −8.53% | +2.32% | +67.25% | +36.55% |
| Today | +1.47% | −0.51% | +1.82% | +1.61% | −1.24% | −0.18% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All YPHA.F news ›Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
Pharmaceutical Executive
Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact
Albany New York October 22 2026 As per DelveInsight s assessment globally Ovarian Cancer pipeline constitutes 180 key companies continuously working towards developing 200 Ovarian Cancer treatment therapies analysis of Clinical Trials…
News from Astellas Pharma Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Astellas Pharma Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 06, 2026, 19:30…
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) and Bristol Myers Squibb (NYSE:BMY – Get Free Report) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of…
Astellas Pharma Adopts Patient-Centric Strategy to Offset Patent Expirations
Astellas Pharma CEO Naoki Okamura has outlined a new corporate strategy centered on a “patient axis” operating model, an expanded portfolio of strategic brands, and the development of new scientific technologies to drive future growth. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
defenseworld.net1
-
geneonline.com1
-
pharmexec.com1
-
prnewswire.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.